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Abstract Purpose: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic
Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3.
The expression pattern of this protein in humanmalignancies has not been reported.
Experimental Design:We investigated Bcl-B expression in normal human tissues and several
types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating
results with tumor stage, histologic grade, and patient survival.
Results:Bcl-B proteinwas strongly expressed in all normal plasma cells but found inonly18% of
multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center
centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48)
specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119),
prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as
in non ^ small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed.
Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in
breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location
(P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer
(P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely,
although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome
(P = 0.01) and more differentiated tumor histology (P < 0.0001).
Conclusions:Tumor-specific alterations in Bcl-B expressionmay define subsets of nonepithelial
and epithelial neoplasms with distinct clinical behaviors.
Defective apoptosis represents one of the six recognized
cardinal features of cancer (1). Bcl-2 family proteins are evo-
lutionarily conserved regulators of cell life and death. In
humans, six antiapoptotic members of the Bcl-2 family have
been identified, including Bcl-2, Bcl-XL, Mcl-1, Bcl-W, Bfl-1, and
Bcl-B (2). Overexpression of Bcl-2 and some other antiapop-
totic members of the Bcl-2 family has been documented in
human cancers (reviewed in ref. 3). Given that investigational
therapies targeting specific Bcl-2 family proteins or their
encoding mRNAs are now in clinical trials, it is important to
define which Bcl-2 family proteins are overexpressed in various
types of cancer, so that appropriate targeted therapies can be
matched to specific malignancies.
Bcl-B (also known as Bcl2-L-10) was the last antiapoptotic
member of the human Bcl-2 family to be identified (4, 5), and
relatively little is known about its in vivo functions. Bcl-B
contains conserved BH1, BH2, BH3-like, and BH4 domains,
as well as a COOH terminal transmembrane domain, typical
of antiapoptotic Bcl-2 family proteins that target intracellular
membranes of mitochondria (4, 5). Dimerization of proapop-
totic and antiapoptotic Bcl-2 family proteins plays an important
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role in controlling their activity (6, 7). The Bcl-B protein was
shown to differentially bind proapoptotic Bcl-2 family mem-
bers (4). Thus, Bcl-B may have a unique pattern of selectivity for
binding to various proapoptotic members of the Bcl-2 family,
suggesting a specific role for this protein in controlling cell life
and death.
Although initially recognized for its antiapoptotic activity, the
mouse orthologue of Bcl-B reportedly displays either antiapop-
totic or proapoptotic activity, depending on cellular context
(8, 9). In this regard, we recently reported that Bcl-B binds
orphan nuclear receptor Nur77/TR3, which converts the pheno-
type of Bcl-B from antiapoptotic to proapoptotic (10). Thus, Bcl-
B is similar to Bcl-2 in its ability to display opposing effects on
apoptosis based on protein interactions and other factors (11).
Heretofore, analysis of Bcl-B protein expression in human
tissues or cancers has not been described. A variety of publicly
available DNA microarray datasets have suggested Bcl-B mRNA
is widely expressed in human tissues and many cancers but
have attracted little attention and permitted few conclusions.
The closest orthologue of Bcl-B in mice is Boo/Diva, with 49%
amino acid identity. However, Boo/Diva expression in mice
seems to be limited to ovary and testis (8, 9), suggesting that
the murine gene is regulated differently than its closest human
counterpart and highlights an important species-specific
difference. By generating monospecific antibodies that recog-
nize Bcl-B, we have investigated Bcl-B protein expression in
normal human tissues and in several types of human malig-
nancy by immunohistochemistry, correlating the expression
results with clinically relevant variables.
Materials andMethods
Patient specimens. Informed consent was obtained in accordance
with the Declaration of Helsinki. This study was approved by the
Institutional Review Boards of each institution that participated.
Bone marrow biopsies from 165 patients, 114 with symptomatic
multiple myeloma (MM), 19 with indolent MM, 13 with monoclonal
gammopathy of undetermined significance (MGUS), and 19 with
reactive plasmacytosis, were obtained from Veterans Affairs Medical
Center (VA Hospital) of Los Angeles. Patients were categorized
according to WHO criteria, assessing the plasma count in bone marrow
(group 1, 0-10%; group 2, 11-30%; group 3, >30%; ref. 12).
Tissue microarrays (TMA) comprising paraffin-embedded lymph
node specimens from 48 patients diagnosed with diffuse large B-cell
lymphomas (DLBCL) and from 57 patients with follicular lymphoma
were provided by the Robert H. Lurie Comprehensive Cancer Center,
Northwestern University.
Tumor specimens were obtained from 79 small cell lung cancer
(SCLC) patients with limited disease who were treated by surgery
followed by chemotherapy using various multidrug regimens at the
Thoracic Surgery Department of Medical University of Gdan˜sk between
1984 and 2001. In addition, thoracic radiation was given to 4% of the
patients and prophylactic cranial irradiation to 8% of the patients.
Patients ranged from clinical stages I to IIIA and were of good
performance status (Karnofsky score, 80-100). Clinical data represent
a median follow up of 1.3 y.
TMAs containing specimens from 82 non-SCLC patients were
obtained from Princess Margaret Hospital and Ontario Cancer Institute
in Toronto. The specimens represented 22 adenocarcinomas, 32
squamous cell carcinomas, and 16 large cell carcinomas (12 unspecified
tumors).
Clinicopathologic characteristics related to paraffin-embedded tissue
specimens containing cervical, colorectal, gastric, breast, prostate, and
ovarian cancers were described elsewhere (13–16). In addition, a TMA
was produced for 26 cases of Crohn’s disease that had been obtained
from the Department of Pathology at Yonsei University Medical Center.
Tissue preparation. The tissues were prepared for paraffin embed-
ding, as described elsewhere (17). TMAs were produced for all
investigated tumors and tissues, as described previously (14).
Antibodies. Glutatione S-transferase (GST)–Bcl-B fusion protein
was produced in bacteria and purified by affinity chromatography as
described (18). A polyclonal antibody specific for Bcl-B (BR-49) was
raised in rabbits using the affinity-purified recombinant GST–Bcl-B
protein as the immunogen. An additional anti–Bcl-B serum (AR-77)
was generated in rabbits using a synthetic peptide (NH2-REPGTPE-
PAPSTPEAAVLR-amide) corresponding to residues 32 to 50 of human
Bcl-B. Commercial mouse monoclonal antibodies included anti-CD138
(Serotec), anti-CD68 (DakoCytomation), anti-CD10 (Novocastra),
anti–Bcl-6 (Novocastra), anti-MUM1 (DakoCytomation), anti–Bcl-2
(DakoCytomation), anti-Hsp60 (Nventa), anti–h-actin (Sigma-Aldrich),
and anti-GST (BD PharMingen).
Immunohistochemistry. Dewaxed tissue sections were immunos-
tained as reported previously (19). To determine specificity, the
immunostaining procedure was done in parallel using preimmune
Bcl-B serum and immune serum (1:1,000) preabsorbed with 10 Ag of
GST–Bcl-B, GST–Bcl-XL recombinant protein, or synthetic peptide
immunogens. The immunostaining scoring system was described
previously (20).
For double-labeling procedure, tissue sections were stained as above
using Bcl-B rabbit polyclonal antiserum (3,3¶-diaminobenzidine chro-
magen, DAKOCytomation; brown) followed by mouse monoclonal
CD138 antibody (Serotec; SG chromagen, Vector Lab., Inc.; black).
Nuclear red (DAKOCytomation) was used for counterstaining of the
double-labeled slides. Automated image analysis system (Aperio
Technology, Inc.) was used to visualize Bcl-B and CD138 staining
separately, applying a color deconvolution algorithm (21). Quantifica-
tion of immunostaining was done using color translation and an
automated thresholding algorithm (Aperio Technology, Inc).
Immunohistochemistry results for CD10, Bcl-6, and MUM1 were
used to subclassify DLBCL cases into GCB and non-GCB categories
(22): cases immunopositive for CD10 alone or for both CD10 and
Bcl-6 were assigned to the GCB group, whereas cases that were CD10-/
Bcl-6- or that were CD10-/Bcl-6+/MUM1+ were considered non-GCB.
Expression plasmids. Bcl-B encoding cDNA in pcDNA3–Bcl-B
plasmid was digested with BamHI and XhoI (Promega), purified
(Qiagen) from a 1% agarose gel, and then ligated with modified
pTRE2hyg plasmid (Clontech) previously digested with the same
restriction enzymes. Proper plasmid construction was confirmed by
restriction enzyme digestion and DNA sequencing.
Stable transfection. Stable transfection was conducted using the
HeLa Tet-On cell line (Clontech), which was derived from the HeLa
cells. This cell line had been stably transfected with the pTet-On
plasmid, which encoded the tetracycline repressor and allowed the
inserted sequence to be inducibly expressed by tetracycline or
doxycycline. The HeLa Tet-On cells were seeded at 50% confluency
and cultured overnight. Transfection was conducted for 3 h using
LipofectAMINE Plus. Transfected cells were cultured in complete media
for 24 h and then split into fresh media. The split cells were seeded to
10% confluence and cultured in media containing G418 (100 Ag/mL)
to maintain the integration of the pTet-On construct and hygromycin B
(300 Ag/mL) to select stable transfectants of pTRE2hyg/Bcl-B. Positive
foci resistant to both antibiotics were isolated and expanded. The
transfected cells were cultured in the presence or absence of doxycycline
(1 Ag/mL) for 16 h for immunoblot studies.
Immunoblotting. Specimens derived from normal and malignant
human tissues with high ratios of cancer cells relative to stroma (>70%)
were provided by M. D. Anderson Cancer Center-Orlando for
immunoblotting analysis. The protein lysate preparations, immuno-
blotting procedures, and antigen detection were described previously
(23). Blots were probed with rabbit anti–Bcl-2 antisera (1:2,000 to
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1:3,000 v/v), mouse anti-Hsp60, or h-actin antibodies. Expression and
purification of recombinant Bcl-2 family proteins are described
elsewhere (10).
Microsatellite instability. Specimens were analyzed for microsatel-
lite instability, as described previously (14).
Statistical analysis . Data were analyzed using the STATISTICA
software package (StatSoft) as described elsewhere (14). Median Bcl-B
immunopercentage and immunoscore (IS) were applied as cutoffs for
Kaplan-Meier survival analyses.
Results
Characterization of Bcl-B antibodies and immunoblot analysis
of normal and malignant human tissues. The specificity of the
BR-49 antibody was documented previously, showing reactivity
with Bcl-B but not Bcl-2, Bcl-XL, Mcl-1, Bcl-W or Bfl-1 (10). To
characterize the specificity of the AR-77 antibody, immunoblot
analysis was done using recombinant Bcl-2 family proteins
generated in bacteria (Fig. 1A and B). The AR-77 antibody
was determined to be specific for Bcl-B, detecting GST fusion
protein containing Bcl-B and lacking cross-reactivity with
other Bcl-2 family members (Fig. 1A and B). Note that the
two bands seen with GST–Bcl-B likely correspond to intact
fusion protein (f45-50 kDa) and proteolyzed protein sepa-
rating Bcl-B (f23 kDa) from GST.
Probing tissue lysates with the AR-77 or BR-49 antibodies
showed reactivity with a protein at f23 kDa, corresponding
to the predicted molecular mass of Bcl-B, as well as f45 to
50 kDa band that seems to be an SDS-resistant dimer, based on
studies that have detected this species even when using epitope-
tagged Bcl-B protein that was detected using antibodies directed
against the tag (not shown). Also, a dimeric form of Bcl-B was
shown by SDS-PAGE analyses of purified recombinant Bcl-B
produced without GST tag (not shown). In some tumor lysates,
bands were detected that may correspond to posttranslationally
modified forms of Bcl-B, which migrate at a few kilo-Daltons
larger apparent molecular mass than monomeric Bcl-B in SDS-
PAGE (see, for example, diffuse large cell lymphoma, MM, and
benign prostatic hyperplasia samples). The specificity of the
anti–Bcl-B antibodies was further confirmed by analysis of
lysates from HeLa cells containing a tetracycline-inducible Bcl-B
construct, revealing the presence of the expected f23 kDa Bcl-
B band only when the tetracycline analogue doxycyclin was
added to cultures (Fig. 1).
Levels of endogenous Bcl-B varied among tissues and tumor
specimens analyzed by immunoblotting. Bcl-B was elevated in
non-SCLC compared with normal lung in two of two paired
specimens and also higher in a colorectal cancer compared with
normal colonic tissue from the same patient (Fig. 1C). In
contrast, Bcl-B protein levels were higher in benign prostatic
hyperplasia specimen compared with a prostate cancer. Bcl-B
protein was also present in three of four diffuse large-cell
lymphoma and two of three MM specimens tested. Reprobing
blot with anti-Hsp60 or anti–h-actin antibodies confirmed
equivalent loading of tissue lysates.
Immunohistochemical analysis of Bcl-B protein expression
in normal human tissues. To lay a foundation for assessing
Bcl-B expression in cancers, we first ascertained the in vivo
patterns of Bcl-B protein expression in normal human tissues
Fig. 1. Characterization of Bcl-B antibodies and immunodetection of Bcl-B protein in human tissue lysates. A, GST fusion proteins containing Bcl-XL, Bfl-1, Bcl-2, Mcl-1,
Bcl-W, and Bcl-B (0.1 Ag/lane) were analyzed by immunoblotting using AR-77 antiserum (top).The blot was reprobed with anti-GST (bottom). Cell lysates from HeLa cells
with tetracycline-inducible Bcl-B are also included (tet on/off). B and C, selected GST fusion proteins (0.05 Ag/lane) and human tissue lysates normalized for total protein
content (50 Ag/lane) were subjected to SDS-PAGE/immunoblot analysis, using AR-77 (1:2,000, v/v; B) or BR-49 (1:3,000, v/v; C) antibodies to Bcl-B (top). Blots were
reprobedwith anti-HSP60 and anti ^h-actin antibodies (bottom). Antibody detectionwas accomplishedusing an enhanced chemiluminescencemethod. Black arrows, Bcl-B
monomers or SDS-resistant Bcl-B dimers; white/black double arrow, GST ^ Bcl-B fusion protein.
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by immunohistochemical analysis. The most intense Bcl-B
immunoreactivity was found in plasma cells. Strongly stained
plasma cells were found in bone marrow, lymphoid tissues, at
sites of inflammation, and infiltrating some tumors (Fig. 2). In
contrast, erythroid cells, myeloid cells, and megakaryocytes in
bone marrow, as well as macrophages, dendritic cells, and most
lymphocytes in nodes and extranodular sites of inflammation
were Bcl-B negative. Immunoblotting analysis of plasma cells
isolated from bone marrow also confirmed the presence of
Bcl-B protein (Supplementary data). Moreover, comparisons of
immune (Fig. 2A) and preimmune serum (Fig. 2B), as well as
preabsorption experiments using GST–Bcl-B (Fig. 2C) or GST–
Bcl-XL fusion proteins (Fig. 2D), confirmed the specificity of
plasma cell immunostaining (also see Supplementary data).
The plasma cell phenotype of the Bcl-B–positive cells was also
confirmed by two-color immunohistochemical analysis, show-
ing coexpression of Bcl-B with CD138 (syndecan-1) expressing
cells (Fig. 2I-L). In contrast, the Bcl-B–positive cells were
negative for the macrophage marker CD68 (not shown) in two-
color immunostainings.
In addition to plasma cells, Bcl-B also immunolocalized to
centroblasts and centrocytes in germinal centers, but not to
other types of cells in lymphoid and hematopoietic tissues
(Fig. 2E and H), including bone marrow, spleen, nodes, and
thymus. The intensity of Bcl-B immunostaining in these
lymphocytes, however, was substantially less than plasma cells
(Fig. 2F-G). Among other normal human tissues, Bcl-B
expression was detected in hepatocytes, renal tubule epitheli-
um, bronchial and nasopharyngeal epithelium, and type II
pneumocytes, as well as cytotrophoblasts in the placenta and
some neuronal cells, again with immunointensity much less
than observed in plasma cells. In the prostate gland, Bcl-B
immunoreactivity was strong in the luminal secretory cells but
was absent in basal cells (Supplementary data), thus constitut-
ing a pattern of expression opposite of Bcl-2 (24). In all cells
examined, the Bcl-B staining pattern was predominantly
cytosolic, with a punctate or granular organellar distribution.
Bcl-B protein expression in hematopoietic malignancies. Due
to the predominant expression of Bcl-B protein in plasma cells,
we investigated expression of Bcl-B in plasma cell dyscrasias.
Bone marrow biopsies were immunohistochemically evaluated
from 165 patients, 114 with symptomatic MM, 19 with
indolent MM, 13 with MGUS, and 19 with reactive plasmacy-
tosis. Unlike normal plasma cells which seemed to be
uniformly Bcl-B–positive, Bcl-B protein was immunolocalized
only to a proportion of plasma cells in the 165 specimens of
plasma cell dyscrasia, with an average prevalence of 29 F 2.1%
immunopositive cells. Only 16% (26 of 165) of all tumors
showed at least 50% immunopositivity for Bcl-B, with 21 of
these high Bcl-B expressors belonging to symptomatic MM
(21 of 114, 18%), 3 to the indolent MM group (3 of 19, 16%),
and 1 each to the MGUS (1 of 13, 8%) and the reactive
plasmacytosis (1 of 19, 5%) groups. Using 5% cutoff, 30%
(49 of 165) of the plasma cell dyscrasia cases were negative for
Bcl-B. Figure 3A-D illustrates examples of Bcl-B immunostain-
ing in malignant plasma cells. No significant differences in Bcl-
B IS values were observed when specimens from MM, MGUS,
and reactive plasmacytosis cases were compared. Similarly,
Bcl-B immunopositivity and IS were comparable in grades 1 to
3, categorized according to WHO criteria regarding plasma
cell content. Bcl-B expression was not significantly associated
with patient age, gender, overall survival, or response to ther-
apy in MM.
Lymph node specimens from 48 DLBCL patients were
investigated by immunohistochemistry for Bcl-B expression
(Fig. 3E-F). Cases were considered positive if z30% of tumor
cells were Bcl-B immunoreactive. Of 48 DLBCL cases, 25 (52%)
were Bcl-B immunopositive, using the 30% cutoff that
corresponded to the median percentage of Bcl-B–positive cells
in this cohort. CD10, Bcl-6, and MUM1 immunostainings were
applied to classify the DLBCL cases into GCB and non-GCB
groups (22), using the same cutoff of z30% (22). In the
investigated patient cohort, 19 of 48 (40%) were considered
GCB and 29 (60%) were classified as non-GCB cases. Both
groups contained almost identical proportions of Bcl-B–
negative and Bcl-B–positive cases (47% and 53%, respectively,
in the GCB group; 48% and 52% in the non-GCB category).
Thus, analysis of the expression of Bcl-B protein in the GCB
and non-GCB lymphomas did not reveal significant differences.
The Bcl-B immunostaining data also did not correlate with
Bcl-2 staining in these DLBCL specimens.
None of the specimens derived from 57 patients with
follicular lymphoma contained detectable Bcl-B immunostain-
ing in malignant B cells (Fig. 3G-H). Positive Bcl-B immuno-
reactivity in plasma cells observed in these specimens provided
an internal staining control.
Bcl-B protein expression in solid tumors. In addition to hema-
topoietic malignancies, Bcl-B protein expression was investigated
in breast, cervical, ovarian, prostate, lung, gastric, and colorectal
cancers. The findings provide evidence of alterations in Bcl-B
protein expression in several types of solid tumors.
Breast cancer. TMAs containing specimens derived from
119 stages I to III breast cancer patients were immunostained
for Bcl-B. The tissue samples comprised 28 cases of DCIS and
104 ductal, 12 lobular, and 3 mucinous invasive carcinomas.
In addition, 12 normal mammary epithelium specimens,
excised from surgical margins, were included on the arrays,
as well as four independent samples of normal mammary
gland tissue. Whereas expression of Bcl-B was below the level
of detection in normal mammary epithelium, Bcl-B immu-
nostaining was prevalent in 64% of in situ carcinomas and
in 89% of invasive cancers (cutoff 10% immunopositive
cells), suggesting increasing expression with breast cancer
progression. Comparison of Bcl-B immunostaining results for
Fig. 2. Immunohistochemical detection of Bcl-B expression in B cells and plasma cells. A-D, serial sections of normal human lymph node specimen were stained with
anti ^ Bcl-B antiserum (A ; raised against recombinant Bcl-B protein; 400), preimmune serum (B ; 100), anti ^ Bcl-B antiserum preabsorbed with GST ^ Bcl-B (C ; 200),
and anti ^ Bcl-B antiserum preabsorbed with GST ^ Bcl-xL (D ; 200). Specimens were counterstained with hematoxylin. Human lymph node (E and F) and spleen (G and
H) sections containing secondary follicles (E andH) were stainedwith the Bcl-B antibody to visualize immunopositive B cells in germinal centers (E andH) and plasma cells
in medullary cords (F) and red pulp (G). Photomicrographs were taken at original magnifications ranging from100 to 400. I-L,TMA containing gut specimens from
patients with Crohn’s disease were double stained with the Bcl-B (3,3¶-diaminobenzidine; brown) and CD138 (SG; black) antibodies and counterstained with nuclear red.
The brown (I) and black (J) colors were separated in the annotated regions using a color deconvolution algorithm (Aperio). Quantification of immunohistochemical staining
for Bcl-B (K) and CD138 (L) was done using color translation and an automated thresholding algorithm (Aperio). Dark red pixels visualize positive immunostaining,
whereas blue pixels depict immunonegative areas. Note colocalization of Bcl-B and CD138 cells. Original magnifications are 100 (I andJ) and 400 (K and L).
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transformed versus normal mammary epithelium was highly
significant (P < 0.0001), using either immunopositivity or IS
data (Figs. 4A-C and 5A).
Significantly higher Bcl-B immunostaining was observed in
invasive ductal compared with invasive lobular carcinoma
(70% versus 47% mean immunopercentage, P = 0.03; 108
versus 59 mean IS, P = 0.02). Higher Bcl-B immunostain-
ing was associated with more advanced stage of disease
(P = 0.01 for immunopercentage; P = 0.004 for IS), more
involved lymph nodes (P = 0.04 for IS), and higher histologic
grade of tumors, with high-grade tumors containing signifi-
cantly higher levels of Bcl-B protein as determined by immu-
nostaining (70 F 3.2% versus 42 F 14.1% immunopositive,
P = 0.02; 108 F 6.4 versus 48 F 17.6 IS, P = 0.009; Fig. 5B).
Fig. 3. Immunohistochemical detection of Bcl-B expression in human hematolymphoid malignancies. Bone marrow biopsies from multiple myeloma patients (A-D) and
lymph node specimens from DLBCL (E and F) and follicular lymphoma (G and H) cases were immunostained using Bcl-B antiserum. Original magnifications are150 (G),
200 (A-C and E), 1000 (D, F, and H), and 800 to 1,200 (insets).
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Bcl-B elevation in invasive tumors was correlated with higher
ER-h expression (r = 0.42, P < 0.0001 for immunopercent-
age; r = 0.37, P < 0.0001 for IS) and with lower PR expres-
sion (r = -0.22, P = 0.02 for IS), but not with ER-a expression.
Breast tumors that showed lymphatic vessel invasion contained
higher levels of Bcl-B protein (P = 0.005 for immunopositivity;
P = 0.0006 for IS).
No correlations were found between Bcl-B expression and
patient age, tumor size, or patient survival. In this particular
cohort of breast cancer patients, only PR was an independent
prognostic factor for overall and disease-free survival in
univariate and multivariate analysis (P = 0.008; P = 0.01,
respectively; Cox regression) among all variables assessed
(patient age, clinical stage, tumor grade, lymphatic vessel
invasion, ER-a, ER-h, PR, Bcl-B% or IS).
Cervical cancer. TMAs containing cervical specimens derived
from Asian women diagnosed with cervical intraepithelial
neoplasia 1 (low-grade squamous intraepithelial lesions;
mild dysplasia; n = 47), cervical intraepithelial neoplasia 2
(high-grade squamous intraepithelial lesion; moderate dyspla-
sia; n = 46), cervical intraepithelial neoplasia 3 (high-grade
squamous intraepithelial lesion; severe dysplasia-carcinoma
in situ; n = 137), and invasive squamous cell carcinoma
(n = 109) were stained for Bcl-B. Normal cervical epithelium
adjacent to the transformed cells was available for each
histologic entity (n = 328) for all patients in the precancerous
groups and 30 of 109 in women diagnosed with invasive
cancer. Barely detectable Bcl-B immunostaining was observed
in normal epithelium of the exocervix (Fig. 4D) and all stages
of the malignant progression (cervical intraepithelial neoplasia
1-3), indicating that Bcl-B expression is not a characteristic
of cervical cancer in this Asian cohort. Strongly stained plasma
cells were found infiltrating many cervical tumors serving as
a positive control (Fig. 4E).
Ovarian cancer. Bcl-B expression was investigated using
TMAs containing tissue specimens from 91 ovarian carcinoma
Fig. 4. Distribution of Bcl-B immunostainings in human nonlymphoid malignancies. Representative Bcl-B immunostaining results are presented for microarrays of breast
specimens in normal mammary epithelium (A ; 60), DCIS (B ; 200), and ductal adenocarcinoma (C ; 60); uterine cervix specimens in normal cervix (D ; 60) and
squamous cervical carcinoma (E ; 200); gastric specimens in normal gastric epithelium (F ; 100; inset, 300) and gastric cancers (G and H; 60); colon specimens in
normal colonic epithelium (I ; 200) and colon cancer (J; 60); and SCLC in primary tumor (K ; 200) and LN metastasis (L ; 200). Note Bcl-B immunopositive plasma
cells in normal (F and I) and malignant (E, J-L) tissues.
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patients and six normal ovarian surface epithelium or fallopian
tube specimens. The patient cohort comprised 62 individuals
with serous carcinomas and 29 cases of nonserous tumors,
including mucinous (n = 13), endometrioid (n = 11), clear
cell (n = 2), granulosa (n = 1), dysgerminoma (n = 1), and
carcinosarcoma (n = 1) types.
Low-intensity Bcl-B immunostaining was detected in ovarian
surface epithelium and normal tubal epithelium, with similar
levels of Bcl-B expression found in ovarian cancers. No sig-
nificant differences in Bcl-B protein levels were noted between
the two broad histologic categories of ovarian cancer—serous
and nonserous. Among these patients, Bcl-B immunostaining
did not correlate with patient age, histologic grade of tumor,
CA125 serum marker, overall or disease-free survival, or re-
sponse to therapy. International Federation of Gynecology and
Obstetrics stages II to IV showed elevated levels of Bcl-B com-
pared with stage I tumors (87 F 7.6 versus 49 F 18.4, for IS)
but the difference was statistically insignificant. Statistical
comparisons done for a more homogenous cohort of ovarian
cancers, namely the 64 serous carcinoma cases, failed to reveal
significant associations between Bcl-B expression and the
clinical variables. Thus, Bcl-B overexpression is not a common
trait of ovarian cancers.
Prostate cancer. To characterize the expression of Bcl-B in
prostate cancers, we used TMAs containing patient specimens
representing the full range of prostate malignant transforma-
tion, including specimens of benign prostatic hyperplasia
(n = 38), prostatic intraepithelial neoplasia (n = 11), and
prostate adenocarcinoma (n = 41) derived from 66 patients.
Gleason score data were available for all tumors, whereas
clinical stage information (T2-T3; according to International
Union against Cancer criteria) was known for 48% of patients.
In addition, nonneoplastic prostate epithelium from 14% of
cases was available for comparison of protein expression in
nontransformed versus neoplastic epithelium.
Low expression of Bcl-B was found in the normal prostatic
epithelium (mean immunopercentage, 18 F 11.6). Bcl-B
expression was markedly increased in benign prostatic hyperpla-
sia (63 F 5%) and prostatic intraepithelial neoplasia (80 F 7%)
lesions, but less so in the invasive cancers (46 F 6%;
P = 0.0003 for immunopercentage, P = 0.01 for IS; Fig. 5C).
Immunohistochemical analysis of specimens revealed higher
Bcl-B levels in high-grade tumors (Gleason grade 4) compared
with tumors with Gleason grade 3; however, the difference did
not reach statistical significance. Higher Bcl-B ISs correlated with
poor clinical outcome, with Bcl-B significantly up-regulated in
Fig. 5. Graphic presentation of Bcl-B immunohistochemistry results in human nonlymphoid malignancies. Box and whisker plots display the distribution of
immunopercentage data for Bcl-B in normal mammary epithelium (NE) versus in situ (IS) and invasive (INV) breast carcinoma (A), and in normal prostatic epithelium (NE)
versus benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and prostate cancer (CA ; C). Box and whisker plots depict Bcl-B IS data for low-grade
versus high-grade breast cancers (B), for prostate tumors from patients who survived (S) or died (D) from cancer (D), and for well (W), moderately (M), and poorly (P)
differentiated gastric cancers (E).Themean immunopercentage/IS is plotted as amarker; whiskers reflectF1.96 SE from themean. F, Bcl-B immunopercentage data for SCLC
were dichotomized into high (red) versus low (blue) expression groups based on the median values.The percentage of patients remaining alive (ordinate) was compounded
over time (abscissa; in y) by the Kaplan-Meier method.The log-rank test was used for correlating the immunostaining data with the patient survival.
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tumors from patients who died from prostate cancer compared
with those who survived without relapse during the follow-up
period (median follow-up, 2.7 years; 65 F 14% versus 33 F 9%
for immunopositivity, P = 0.05; 126 F 30 versus 43 F 18 for IS,
P = 0.005; Fig. 5D). Comparison of preoperational PSA levels
suggested that intratumoral Bcl-B is higher in patients with higher
PSA levels, but the results did not reach statistical significance.
Gastric cancer. Archival gastric specimens from 169 Asian
patients who underwent surgical resection for localized gastric
cancer were analyzed immunohistochemically for Bcl-B protein
expression. Bcl-B was expressed in normal gastric surface epi-
thelium, but glands deep within the gastric mucosa were negative
for Bcl-B or contained only trace amounts of this protein (Fig. 4F).
Expression of Bcl-B was prevalent in gastric cancers, with
89% of tumors showing z10% immunopositive cells. Bcl-B
protein was significantly associated with histologic architecture
and cellular differentiation of gastric adenocarcinomas, with
higher levels of Bcl-B expression in well-differentiated tumors
compared with poorly differentiated tumors (90 F 2.4% versus
52F 3%, P < 0.0001 and 155 F 8 versus 69F 5 IS, P < 0.0001;
Fig. 5E) and higher Bcl-B levels in intestinal-type (Fig. 4G)
compared with diffuse-type cancers (Fig. 4H; P < 0.0001).
Similarly, Bcl-B levels in tumors containing signet ring cells
were lower than those in non–signet ring cell tumors (43 F
10.0% versus 75 F 3%, P < 0.0001 and 59 F 17 versus 118 F
6 IS, P < 0.0001). Interestingly, tumors with prominent
lymphoid infiltration showed higher Bcl-B protein content
compared with those that were not infiltrated by lymphocytes
(P = 0.01 for immunopositivity, P = 0.009 for IS).
Although tumors from patients who died from cancer
contained slightly lower levels of Bcl-B protein compared with
tumors from those who survived (P = 0.01 for IS), no significant
association with overall survival or disease-free survival was
observed for this patient cohort using Kaplan-Meier survival
analysis and log-rank test analysis. Also, Bcl-B expression did not
correlate with the clinical stage or mucin content in tumors.
Colorectal cancer. TMAs were constructed using primary
tumor specimens derived from a cohort of 106 Asian patients
with stage II colorectal cancer, who were treated by surgical
resection with curative intent. Of the 106 selected cases, 63
patients survived without recurrence, 7 patients had recurrent
disease, and 36 patients died from colorectal cancer. Thus,
while not an unbiased sequential case series, the survival profile
of this cohort closely resembles that of a random population
of stage II colorectal cancer patients, with 72.5% of individuals
alive at 5 years. Adjacent normal colonic mucosa was present in
65% of the 106 tumor specimens on the array, permitting side-
by-side comparisons of immunostaining results for morpho-
logically normal versus malignant epithelium. In addition, four
specimens of normal colon derived from individuals who were
not diagnosed with colon cancer were stained separately.
Significantly higher Bcl-B protein expression was found in
colorectal cancers (Fig. 4J) compared with normal colonic
epithelium (Fig. 4I), as assessed by percentage of immuno-
positive cells (64 F 5% versus 92 F 1%) and IS (82 F 7 versus
181 F 6, P < 0.0001 and P = 0.004, respectively). To explore if
differences in Bcl-B protein expression may correlate with
previously identified prognostic features (25), we compared
Bcl-B immunostaining with microsatellite instability status,
anatomic location of tumors, patient gender, and age. In the
investigated cohort, higher Bcl-B levels were found in micro-
satellite stable compared with microsatellite instability tumors
(P = 0.0002 for immunopositivity, P = 0.004 for IS) and in the
left-sided compared with right-sided adenocarcinomas (P = 0.02
for immunopositivity; P = 0.04 for IS). Age and gender were
not associated with Bcl-B expression. In univariate analysis, no
correlations were observed between overall or disease-free
survival and Bcl-B immunostaining data.
Because sections from this same TMA had previously been
analyzed by immunohistochemistry for expression of some
other Bcl-2-family proteins (13), we compared Bcl-B immu-
nostaining data with Bcl-2, Bcl-XL, Bax, and Bid. Bcl-B
immunostaining in colorectal cancers correlated with Bcl-XL
(r = 0.43, P < 0.0001 for IS) and Bax (r = 0.24, P = 0.03 for IS),
but not with Bcl-2 or Bid.
SCLC. Immunostaining for Bcl-B was done on SCLC pri-
mary tumors obtained by hemithoracotomy from 79 patients
with limited stage disease. The cohort comprised 76% men and
24% women with median age of 57 years, among whom 53%
were diagnosed with nonspecified SCLC type, 27% with inter-
mediate, 11% mixed intermediate, 5% fusiform/spindle, 3% oat
cell, and 1% with polygonal carcinoma. In addition to primary
tumors, matching metastatic mediastinal lymph nodes derived
from 24 patients in this cohort were available for investigation.
No significant differences in Bcl-B levels were observed
between primary (Fig. 4K) and metastatic tumors (Fig. 4L), as
determined by paired t test. Higher Bcl-B content was found
in primary tumors from men (P = 0.004 for immunoposi-
tivity, P = 0.02 for IS) and from older patients (P = 0.003 for
immunopositivity, P = 0.01 for IS). No association was noted
between performance status, clinical stage (tumor-node
metastasis and Unio Internationale Contra Cancrum stage),
tumor size or site (left/right lung), and Bcl-B protein levels in
tumors.
To investigate possible association of Bcl-B expression with
clinical outcome, Bcl-B immunopercentage and IS data were
dichotomized at the median values into ‘‘low’’ versus ‘‘high’’
expression groups. High Bcl-B prevalence correlated with
shorter overall survival (log-rank test P = 0.009; Fig. 5F) and
increased relative risk of death due to SCLC (univariate Cox
proportional hazards analysis, hazard ratio 2.4 and 95%
confidence interval 1.3-4.7; P = 0.008). However, in multivar-
iate Cox analysis, which included patient age, gender, clinical
stage, and tumor size and site, Bcl-B did not show independent
prognostic significance. Bcl-B immunostaining data also did
not significantly correlate with time to recurrence after surgery
and chemotherapy, although a trend toward higher Bcl-B and
shorter time was noted (median, 4.9 versus 3.5 years).
Non-SCLC. TMAs containing specimens from 82 non-SCLC
patients were immunohistochemically analyzed for Bcl-B
protein expression, including 22 adenocarcinomas, 32 squa-
mous cell carcinomas, 16 large cell carcinomas, and 12
unspecified tumors. Large cell tumors contained relatively low
Bcl-B expression (81 F 15 IS), adenocarcinomas showed inter-
mediate expression (126 F 20 IS), and squamous cell carci-
nomas revealed higher Bcl-B content (154 F 14 IS; P = 0.005).
No follow-up data were available for these non-SCLC patients.
Discussion
We surveyed Bcl-B protein expression by immunohistochem-
ical methods in normal human tissues and several types of
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malignancy. Our findings provide evidence of cancer-associated
alterations in Bcl-B expression, suggesting that Bcl-B may con-
tribute to pathogenesis or progression of human cancers and indi-
cating that Bcl-B should be considered when tailoring selection of
targeted therapies directed against Bcl-2 family members.
Although most hematopoietic cells exhibited negligible Bcl-B
immunoreactivity, normal plasma cells uniformly contained
intense Bcl-B immunostaining, suggesting that expression of this
member of the Bcl-2 family is induced during terminal stages of
B-cell differentiation. Modest intensity Bcl-B immunoreactivity
was found in a subpopulation of germinal center B cells, raising
the possibility that Bcl-B is initially induced in these antigenic
response regions of nodes, from which plasmablasts arise. The
presence of Bcl-B protein, not only in the short-lived plasma cells
in splenic red pulp and lymph node medullary cords but also in
the long-lived plasma cells in bone marrow, suggests a possible
role for Bcl-B in maintaining survival of these cells in vivo. Given
that autoantibody-producing plasma cells are a recognized
source of persistent allergy and autoimmunity (26), Bcl-B might
be an attractive target for novel therapies for diseases where
autoantibodies secreted by long-lived plasma cells contribute to
pathology (reviewed in refs. 27, 28). Therapies designed to target
B lineage cells, such as radiation, immunosuppression (predni-
sone, cyclophosphamide), and anti-CD20 antibodies do not
eradicate nondividing long-lived plasma cells in their survival
niches (29). Heretofore, the elimination of these cells has been
achieved only by complete immunoablation using antithymo-
cyte globulin, but specific targeting of long-lived plasma cells
remains unattainable (reviewed in ref. 28).
MM, which arises because of clonal expansion of plasma cells,
remains largely incurable, with only 10% of patients surviving
10 years after diagnosis. In multiple studies, increased levels of
antiapoptotic Bcl-2, Bcl-XL, and Mcl-1 proteins were linked to
survival ofMM cells and resistance to chemotherapy (reviewed in
ref. 30). Experimentally reducing expression or function of
antiapoptotic Bcl-2 famly proteins was shown to sensitize MM
cells to various chemotherapeutic agents (30–32). Expression of
Bcl-B in myeloma may indicate a role for this protein in the
pathogenesis of this malignancy or could simply be a concom-
itant of a plasma cell phenotype. In fact, the observation that
essentially all normal plasma cells express Bcl-B, whereas only
18% of myelomas show prominent Bcl-B expression, suggests
that Bcl-B expression is not pathologically elevated in myelomas
and implies that Bcl-B–negative myelomas may represent a
more immature stage of plasma cell differentiation compared
with terminally differentiated, nonproliferating, normal plasma
cells. Alternatively, because Bcl-B is converted from a protector
to a killer through interactions with Nur77/TR3 (10), absence of
Bcl-B may reflect a proapoptotic role for Bcl-B in MM.
Among epithelial neoplasms examined in this study, cancer-
specific overexpression of Bcl-B protein was commonly observed
in breast, prostate, gastric, colorectal, and lung adenocarcinomas,
where tumor immunostaining was clearly stronger in intensity
than corresponding normal epithelial cells in those tissues.
Prominent expression of Bcl-B was also found for SCLC.
However, it is unclear whether the high Bcl-B immunostaining
in SCLC is indicative of tumor-associated overexpression versus a
reflection of a normal profile for the neuroendocrine cells from
which these cancers arise. Nevertheless, these findings document
for the first time that high level expression of Bcl-B is a common
feature of several types of human malignancy.
The functional significance of Bcl-B expression in epithelial
malignancies remains to be determined. From a correlative
stand-point, Bcl-B expression was associated with variables of
poor prognosis in breast and colorectal cancer, greater incidence
of death from prostate cancer, and shorter survival as well as
increased relative risk of death from SCLC, suggesting Bcl-B may
contribute to aggressive behaviors of these tumors. Conversely,
Bcl-B protein expression was not pronounced in cervical or
ovarian cancers, suggesting that Bcl-B is not commonly involved
in these malignancies. Also, whereas Bcl-B was overexpressed in
many gastric cancers, it tended to correlate with better outcome
and more differentiated (lower grade) histology.
In considering the consequence of elevated Bcl-B expression in
human tumors, it should also be considered that both pro-
apoptotic and antiapoptotic Bcl-2 family proteins are known to
change their respective phenotypes in certain scenarios (reviewed
in ref. 33). For example, Bcl-2 and Bcl-XL can be converted by
caspases from cytoprotective to lethal proteins (34, 35). Also,
binding of Nur77/TR3 to Bcl-2, Bfl-1, or Bcl-B converts these
normally antiapoptotic proteins to proapoptotic killers (10, 11).
Additionally, Bcl-XL expression was associated with increased
apoptosis under circumstances where K-Ras is targeted to
mitochondria (36). Thus, Bcl-B may play opposing roles in
apoptosis regulation depending on cellular context.
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